FDA turns down high doses of Merck's insomnia drug suvorexant

07/3/2013 | Zacks · MedPage Today (free registration)

Merck failed to obtain the FDA's approval for higher doses of its experimental insomnia drug suvorexant. The agency sent Merck a complete-response letter saying that safety data don't support the approval of 30- and 40-milligram doses. A 10-milligram dose of suvorexant should be the starting dose for the majority of patients, the FDA said.

View Full Article in:

Zacks · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC